SNPs are single-letter variations within the four-letter DNA alphabet. They are increasingly recognized as having an important role in disease progression.
"Ultimately, these markers could be used in the clinic, along with other known predictors that are used to assess tumor aggressiveness, such as a high Gleason score, to identify men with a high-risk profile," Stanford says in a news release.
About 200,000 prostate cancers are diagnosed each year in the U.S. About 30,000 men die of the disease.
Often prostate cancer is slow growing. Men with the disease often die of other causes before the malignancy turns deadly.
But prostate cancer patients are usually treated with either surgery or radiation because there is no reliable way to determine if an individual patient's prostate cancer is slow growing or aggressive, William Phelps, PhD, of the American Cancer Society tells WebMD.
In the newly published study, Stanford and colleagues analyzed DNA samples from 1,309 Seattle-based prostate cancer patients, looking for gene variants suspected of being involved in tumor progression.
The analysis of 156 candidate genes identified 22 SNPs linked to prostate cancer-specific death.
In a separate analysis, the researchers examined these variants in stored DNA samples from close to 2,900 prostate cancer patients in Sweden who had been followed for an average of six and a half years.